Ozempic is making its presence known on menus, and the forecast for dumplings is 100% sunshine.

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

New guidelines for diabetes treatment, mpox research, and healthcare system improvements discussed in comprehensive health ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

Only 13 states currently allow Medicaid to cover GLP-1 agonist drugs for obesity treatment, highlighting a significant gap in ...

THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in ...

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist danuglipron ... which has a long list of candidates in ...

which are both based on the GLP-1 receptor agonist. Wegovy and Ozempic remain on the FDA's shortages list, despite strenuous efforts by Novo Nordisk to ramp up its production capacity for semaglutide.

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

Embargoed until 4 a.m. CT/5 a.m. ET, Monday, Nov. 11, 2024 DALLAS, Nov. 11, 2024 — GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.